Financial Performance - The company's revenue for Q1 2025 was CNY 954,215,143.94, representing a slight increase of 0.28% compared to CNY 951,504,195.36 in the same period last year[3]. - Net profit attributable to shareholders increased by 8.90% to CNY 68,640,679.60 from CNY 63,029,722.56 year-on-year[3]. - The company's basic earnings per share rose by 9.55% to CNY 0.2926 from CNY 0.2671 in the same period last year[3]. - Net profit for the current period was ¥56,487,064.91, compared to ¥53,871,136.53 in the previous period, representing an increase of approximately 3.0%[29]. - The net profit attributable to the parent company was ¥68,640,679.60, up from ¥63,029,722.56, indicating a growth of around 8.5%[29]. - Basic and diluted earnings per share improved to ¥0.2926 from ¥0.2671, showing an increase of about 9.9%[30]. Cash Flow - The net cash flow from operating activities improved significantly to CNY 63,522,487.01, compared to a negative cash flow of CNY -72,301,258.02 in the previous year[8]. - Cash flow from operating activities was ¥1,167,076,628.12, compared to ¥918,338,578.40 in the previous period, indicating a significant increase in cash inflow[32]. - Net cash flow from operating activities was 72.30 million in the previous period[33]. - The ending balance of cash and cash equivalents was 403.85 million at the end of the previous year[33]. - Cash inflow from operating activities amounted to 928.32 million year-over-year[33]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 5,614,182,320.66, up 2.34% from CNY 5,486,023,079.85 at the end of the previous year[3]. - The total liabilities increased to ¥2,899,981,514.55 from ¥2,844,825,104.64, reflecting a rise of about 1.9%[27]. - Total equity attributable to the parent company rose to ¥2,591,182,217.68 from ¥2,505,833,682.05, an increase of approximately 3.4%[27]. Shareholder Information - The largest shareholder, Guangdong Guanghui Investment Co., holds 42.60% of the shares, totaling 101,088,000 shares[11]. - Lin Peiqing, a natural person, holds 9.09% of the shares, amounting to 21,565,440 shares, with 16,848,000 shares being his own and 4,717,400 shares held in trust[11]. - Chen Qiong, another natural person, owns 5.54% of the shares, which is 13,141,440 shares, with 3,285,360 shares released from restrictions this period[14]. - The company has implemented a 2025 restricted stock incentive plan, which was approved on January 10, 2023[15]. - The total number of restricted shares at the end of the period is 39,569,828 shares, after 3,327,676 shares were released this period[14]. - The company has a total of 41,496,504 restricted shares at the beginning of the period, with 1,401,000 shares added this period[14]. - The company’s actual controllers are Lin Peiqing and Chen Qiong, who are married[11]. - The shareholding structure indicates significant control by a few key individuals and entities, with the top 10 shareholders holding substantial stakes[11]. Financial Expenses and Investments - Financial expenses increased by 38.46% to CNY 22,265,559.88, primarily due to higher interest expenses[7]. - The company plans to invest up to 249.48 million, up from 12.12 million, compared to $6.43 million in the prior year[33]. Other Financial Metrics - The weighted average return on equity slightly decreased to 2.70% from 2.73% year-on-year[3]. - The company reported a decrease in research and development expenses to ¥29,103,485.10 from ¥30,794,385.11, a reduction of approximately 5.5%[29]. - The company received government subsidies amounting to CNY 1,183,139.40, which positively impacted its financial performance[4]. - Other comprehensive income after tax for the current period was ¥13,655,659.94, a recovery from a loss of ¥26,692,941.41 in the previous period[30].
仙乐健康(300791) - 2025 Q1 - 季度财报